PLCXD1: A Potential Drug Target and Biomarker (G55344)

Target Name: PLCXD1

NCBI ID: G55344

PLCXD1

PLCXD1: A Potential Drug Target and Biomarker

PLCXD1 (OTTHUMP00000024275) is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. It is a member of the superfamily of Eukaryotic translation initiation factors (S/TIs), which are involved in the initiation of protein synthesis in eukaryotic cells. PLCXD1 is identified as a potential drug target or biomarker due to its unique function and the involvement of several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

PLCXD1 function and localization

PLCXD1 is a 21-kDa protein that is expressed in a variety of tissues, including the brain, heart, and liver. It is primarily localized to the cytoplasm of eukaryotic cells and is also found in the endoplasmic reticulum (ER) and the nuclear pore complex (NPC). PLCXD1 is involved in the initiation of protein synthesis by binding to specific eukaryotic translation factors, including eIF4F, which is a key component of the eukaryotic translation machinery.

PLCXD1 and disease

The involvement of PLCXD1 in several diseases and conditions has led to its potential as a drug target or biomarker. PLCXD1 has been shown to be involved in the development and progression of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. In addition, PLCXD1 has also been associated with the development of cardiovascular diseases, including myocardial infarction, stroke, and heart failure.

PLCXD1 has also been shown to be involved in the development and progression of cancer, including breast cancer, ovarian cancer, and colorectal cancer. In these cases, PLCXD1 has been shown to promote the growth and survival of cancer cells, and may also play a role in the development of resistance to chemotherapy.

PLCXD1 as a drug target

The potential drug target for PLCXD1 is based on its involvement in the initiation of protein synthesis and its association with several diseases. Several studies have shown that PLCXD1 can be targeted with small molecules, including inhibitors of the translation of specific proteins that are known to interact with PLCXD1. These inhibitors have been shown to reduce the growth and survival of cancer cells, including human cancer cells that are resistant to chemotherapy.

In addition, PLCXD1 has also been shown to be involved in the regulation of cellular processes that are important for cancer progression, such as cell migration and the angiogenesis that supports tumor growth. Therefore, inhibitors of PLCXD1 have been shown to be effective in treating several types of cancer, including breast, ovarian, and colorectal cancer.

PLCXD1 as a biomarker

PLCXD1 has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The expression of PLCXD1 has been shown to be elevated in a variety of cancer tissues, including breast, ovarian, and colorectal cancer. In addition, PLCXD1 has been shown to be elevated in the brains of individuals with Alzheimer's disease and in the hearts of individuals with heart failure.

The potential use of PLCXD1 as a biomarker for disease has led to several studies aimed at identifying potential biomarkers for PLCXD1-related diseases. For example, researchers have used transcriptomics and other molecular tools to identify differentially expressed genes in PLCXD1-positive cancer tissues

Protein Name: Phosphatidylinositol Specific Phospholipase C X Domain Containing 1

The "PLCXD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLCXD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets